Opus Genetics Inc (IRD)

$3.69 +0.04 (1.10%)
Market Cap 301.67M
Revenue (ttm) 14.20M
Net Income (ttm) -49.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -349.23%
Debt to Equity Ratio -2.69
Volume 752,800
Avg Vol 962,404
Day's Range N/A - N/A
Shares Out 82.65M
Stochastic %K 35%
Beta 0.59
Analysts Strong Sell
Price Target $10.55

Company Profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
BiotechButterflies
BiotechButterflies Aug. 18 at 11:27 PM
$IRD . wow... still for sale under $4..... this when I first chanced upon these folks my file note said "small but cool, have a bite and let it run..." - thats was under $1 and they've done lots since... lots good value added
0 · Reply
TheAliAbdul
TheAliAbdul Aug. 14 at 10:12 PM
$IRD will this stay between $3.5-4.00 till data readout?
0 · Reply
signaljumper
signaljumper Aug. 12 at 9:45 AM
$IRD lets do the 4$ JUMP
0 · Reply
signaljumper
signaljumper Aug. 11 at 8:02 PM
$IRD new Stockreport. Upcoming catalysts, deep dive into the fundamental Data und Chart Updates. Sign in for free https://www.patreon.com/posts/166171957?utm_campaign=postshare_creator&utm_content=android_share&utm_source=twitter
0 · Reply
signaljumper
signaljumper Aug. 9 at 8:42 AM
$IRD Opus Genetics Full Stock Report Sign in for free to unlock the full company deep dive, valuation & chart analysis. 👉 Read the full report. https://www.patreon.com/signaljumper/posts/ird-opus-inc-09-166171957?utm_medium=social&utm_source=twitter&utm_campaign=postshare_creator&utm_content=join_link
1 · Reply
prismmarketview
prismmarketview Aug. 8 at 5:24 PM
August 8 is International Ophthalmology Day. This day celebrates ophthalmologists who dedicate their expertise to protecting one of our most valuable senses. $IRD, $HROW, $OKYO, $BLTE, $OCUL
0 · Reply
TheAliAbdul
TheAliAbdul Aug. 6 at 10:44 AM
$IRD earnings this week?
0 · Reply
signaljumper
signaljumper Aug. 4 at 10:29 AM
$IRD at the Moment we are in a downtrend Chanel. So a Close above 4$ and we broker Out . Lets get IRD bullish again. Oktober Data readout
1 · Reply
TheAliAbdul
TheAliAbdul Aug. 3 at 10:43 PM
$IRD other Boitechs seem to rocket 100% after the slightest good news atm, hope we get our day in September.
0 · Reply
signaljumper
signaljumper Jul. 30 at 9:46 PM
$IRD load the boat 4.50$ Close above and we will See nee 52 week highs very soon
0 · Reply
Latest News on IRD
Opus Genetics price target lowered to $9 from $10 at RBC Capital

2026-08-07T12:25:24.000Z - 12 days ago

Opus Genetics price target lowered to $9 from $10 at RBC Capital

Opus Genetics Registration statement: Registration filing

Aug 7, 2026, 8:00 AM EDT - 12 days ago

Opus Genetics Registration statement: Registration filing

Opus Genetics files $300M mixed securities shelf

2026-08-07T10:25:56.000Z - 12 days ago

Opus Genetics files $300M mixed securities shelf

Opus Genetics reports Q2 EPS (14c), consensus (16c)

2026-08-06T11:20:54.000Z - 13 days ago

Opus Genetics reports Q2 EPS (14c), consensus (16c)

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Opus Genetics Earnings release: Q2 2026

Opus Genetics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Opus Genetics Quarterly report: Q2 2026

Opus Genetics enrolls last patient in OPGx-LCA5 trial

2026-08-03T11:50:12.000Z - 16 days ago

Opus Genetics enrolls last patient in OPGx-LCA5 trial

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics initiated with a Buy at TD Cowen

2026-07-29T09:35:19.000Z - 21 days ago

Opus Genetics initiated with a Buy at TD Cowen

Opus Genetics sets September timeline for retinal disease trial data

2026-07-09T13:10:10.000Z - 5 weeks ago

Opus Genetics sets September timeline for retinal disease trial data

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Jul 9, 2026, 7:00 AM EDT - 5 weeks ago

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics FDA alignment further de-risks path to market, says Chardan

2026-07-06T13:55:20.000Z - 6 weeks ago

Opus Genetics FDA alignment further de-risks path to market, says Chardan

Opus Genetics announces FDA alignment on OPGx-LCA5 trial

2026-07-06T11:10:18.000Z - 6 weeks ago

Opus Genetics announces FDA alignment on OPGx-LCA5 trial

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

Jul 6, 2026, 7:00 AM EDT - 6 weeks ago

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes

2026-06-26T13:20:37.000Z - 7 weeks ago

Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

Jun 26, 2026, 9:15 AM EDT - 7 weeks ago

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

Opus Genetics initiated with an Outperform at RBC Capital

2026-06-23T11:14:14.000Z - 2 months ago

Opus Genetics initiated with an Outperform at RBC Capital

Opus Genetics assumed with a Buy at Chardan

2026-06-18T00:25:07.000Z - 2 months ago

Opus Genetics assumed with a Buy at Chardan

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Jun 16, 2026, 4:05 PM EDT - 2 months ago

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics Transcript: R&D Day 2026

Jun 16, 2026, 10:00 AM EDT - 2 months ago

Opus Genetics Transcript: R&D Day 2026

Opus Genetics Slides: FY 2026

Jun 16, 2026, 10:00 AM EDT - 2 months ago

Opus Genetics Slides: FY 2026

Opus Genetics management to meet with BTIG

2026-06-12T17:40:25.000Z - 2 months ago

Opus Genetics management to meet with BTIG

Opus Genetics registers to sell 2.68M shares of common stock for holders

2026-06-05T20:35:10.000Z - 2 months ago

Opus Genetics registers to sell 2.68M shares of common stock for holders

Opus Genetics Registration statement: Registration filing

Jun 5, 2026, 8:00 AM EDT - 2 months ago

Opus Genetics Registration statement: Registration filing

Opus Genetics initiated with a Buy at Guggenheim

2026-06-04T10:16:57.000Z - 2 months ago

Opus Genetics initiated with a Buy at Guggenheim

Opus Genetics management to meet with Citizens

2026-06-03T17:55:11.000Z - 2 months ago

Opus Genetics management to meet with Citizens

Opus Genetics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:45 AM EDT - 2 months ago

Opus Genetics Transcript: Jefferies Global Healthcare Conference 2026

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Jun 2, 2026, 7:00 AM EDT - 2 months ago

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics Slides: Investor presentation

May 30, 2026, 7:00 AM EDT - 2 months ago

Opus Genetics Slides: Investor presentation

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2026, 4:01 PM EDT - 2 months ago

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

May 27, 2026, 8:00 AM EDT - 3 months ago

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

Opus Genetics initiated with an Outperform at Leerink

2026-05-21T10:33:45.000Z - 3 months ago

Opus Genetics initiated with an Outperform at Leerink

Opus Genetics initiated with an Outperform at Leerink

2026-05-21T10:17:22.000Z - 3 months ago

Opus Genetics initiated with an Outperform at Leerink

Opus Genetics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:00 AM EDT - 3 months ago

Opus Genetics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Opus Genetics Slides: Corporate presentation

May 17, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics Slides: Corporate presentation

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

May 13, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

Opus Genetics price target lowered to $11 from $12 at Citizens

2026-05-13T09:57:18.000Z - 3 months ago

Opus Genetics price target lowered to $11 from $12 at Citizens

Opus Genetics reports Q1 EPS (75c), consensus (14c)

2026-05-12T12:00:32.000Z - 3 months ago

Opus Genetics reports Q1 EPS (75c), consensus (14c)

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics Quarterly report: Q1 2026

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

May 7, 2026, 4:30 PM EDT - 3 months ago

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

May 7, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

May 4, 2026, 4:30 PM EDT - 3 months ago

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Opus Genetics Registration statement: Registration filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Opus Genetics Registration statement: Registration filing

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 10, 2026, 6:59 AM EDT - 4 months ago

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Apr 6, 2026, 7:00 AM EDT - 4 months ago

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Mar 24, 2026, 7:00 AM EDT - 5 months ago

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Opus Genetics Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Proxy statement: Proxy filing

Opus Genetics Slides: Corporate presentation

Mar 16, 2026, 7:11 PM EDT - 5 months ago

Opus Genetics Slides: Corporate presentation

Opus Genetics Registration statement: Registration filing

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Registration statement: Registration filing

Opus Genetics Proxy statement: Proxy filing

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Proxy statement: Proxy filing

Opus Genetics Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Earnings release: Q4 2025

Opus Genetics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Annual report: Q4 2025

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Mar 3, 2026, 8:00 AM EST - 6 months ago

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Feb 27, 2026, 10:10 AM EST - 6 months ago

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Feb 25, 2026, 6:59 AM EST - 6 months ago

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Announces $25 Million Private Placement

Feb 13, 2026, 7:30 AM EST - 6 months ago

Opus Genetics Announces $25 Million Private Placement

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Feb 2, 2026, 8:00 AM EST - 7 months ago

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Jan 27, 2026, 7:00 AM EST - 7 months ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Opus Genetics Transcript: 44th Annual J.P. Morgan Healthcare conference

Jan 15, 2026, 11:15 AM EST - 7 months ago

Opus Genetics Transcript: 44th Annual J.P. Morgan Healthcare conference

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Jan 8, 2026, 7:00 AM EST - 7 months ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 4:01 PM EST - 8 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 8 months ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Dec 9, 2025, 7:00 AM EST - 9 months ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 20, 2025, 8:00 AM EST - 9 months ago

Opus Genetics to Participate in Upcoming Investment Conferences

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 13, 2025, 7:00 AM EST - 9 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 10 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Opus Genetics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Opus Genetics Earnings release: Q3 2025

Opus Genetics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Opus Genetics Quarterly report: Q3 2025

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 10 months ago

Opus Genetics Announces $23 Million Registered Direct Offering

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Nov 6, 2025, 7:00 AM EST - 10 months ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Oct 2, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics Transcript: Study result

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Opus Genetics Transcript: Study result

Opus Genetics Press release: Study result

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Opus Genetics Press release: Study result

Opus Genetics Slides: Study result

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Opus Genetics Slides: Study result

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Sep 30, 2025, 7:00 AM EDT - 11 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 27, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 18, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 1 year ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Opus Genetics Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Opus Genetics Earnings release: Q2 2025

Opus Genetics Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Opus Genetics Quarterly report: Q2 2025

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 4:30 PM EDT - 1 year ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Transcript: Investor update

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Transcript: Investor update

Opus Genetics Press release: Investor update

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Press release: Investor update

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 26, 2025, 6:55 AM EDT - 1 year ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

BiotechButterflies
BiotechButterflies Aug. 18 at 11:27 PM
$IRD . wow... still for sale under $4..... this when I first chanced upon these folks my file note said "small but cool, have a bite and let it run..." - thats was under $1 and they've done lots since... lots good value added
0 · Reply
TheAliAbdul
TheAliAbdul Aug. 14 at 10:12 PM
$IRD will this stay between $3.5-4.00 till data readout?
0 · Reply
signaljumper
signaljumper Aug. 12 at 9:45 AM
$IRD lets do the 4$ JUMP
0 · Reply
signaljumper
signaljumper Aug. 11 at 8:02 PM
$IRD new Stockreport. Upcoming catalysts, deep dive into the fundamental Data und Chart Updates. Sign in for free https://www.patreon.com/posts/166171957?utm_campaign=postshare_creator&utm_content=android_share&utm_source=twitter
0 · Reply
signaljumper
signaljumper Aug. 9 at 8:42 AM
$IRD Opus Genetics Full Stock Report Sign in for free to unlock the full company deep dive, valuation & chart analysis. 👉 Read the full report. https://www.patreon.com/signaljumper/posts/ird-opus-inc-09-166171957?utm_medium=social&utm_source=twitter&utm_campaign=postshare_creator&utm_content=join_link
1 · Reply
prismmarketview
prismmarketview Aug. 8 at 5:24 PM
August 8 is International Ophthalmology Day. This day celebrates ophthalmologists who dedicate their expertise to protecting one of our most valuable senses. $IRD, $HROW, $OKYO, $BLTE, $OCUL
0 · Reply
TheAliAbdul
TheAliAbdul Aug. 6 at 10:44 AM
$IRD earnings this week?
0 · Reply
signaljumper
signaljumper Aug. 4 at 10:29 AM
$IRD at the Moment we are in a downtrend Chanel. So a Close above 4$ and we broker Out . Lets get IRD bullish again. Oktober Data readout
1 · Reply
TheAliAbdul
TheAliAbdul Aug. 3 at 10:43 PM
$IRD other Boitechs seem to rocket 100% after the slightest good news atm, hope we get our day in September.
0 · Reply
signaljumper
signaljumper Jul. 30 at 9:46 PM
$IRD load the boat 4.50$ Close above and we will See nee 52 week highs very soon
0 · Reply
BiotechButterflies
BiotechButterflies Jul. 30 at 9:36 PM
$IRD ... a fast recovery last few days.... seemed strange when dipped below $4 and even stranger when approached $3.... had me wondering if I missed something... these folks just keep rolling and rolling good stuff...
0 · Reply
BiotechSheff
BiotechSheff Jul. 30 at 7:21 PM
$IRD ..$3.80 … solid catalyst here w/ it being 2nd week of September . Solid move today!
0 · Reply
gumby361
gumby361 Jul. 27 at 8:52 PM
$IRD ramping up again
0 · Reply
JussieLivermore
JussieLivermore Jul. 24 at 1:53 PM
$IRD Adding, expecting support around AVWAP from all time lows $2.83
1 · Reply
TheAliAbdul
TheAliAbdul Jul. 24 at 10:59 AM
$IRD will look to buy back in between $2.30-$2.60 think it’s will bottom out in that area.
1 · Reply
JussieLivermore
JussieLivermore Jul. 23 at 3:39 PM
$IRD Picking up shares in low $2.90's
0 · Reply
TheAliAbdul
TheAliAbdul Jul. 16 at 2:41 PM
$IRD trying to figure out where would be appropriate to buy back in, seems to break through every support level.
0 · Reply
WolfOf_MyStreet
WolfOf_MyStreet Jul. 14 at 6:28 PM
$IRD looks like it wants to bounce off the 200 day MA.
0 · Reply
TheAliAbdul
TheAliAbdul Jul. 10 at 2:09 PM
$IRD company blackout on news till middle of September, might as well switch this board off till then
1 · Reply
signaljumper
signaljumper Jul. 1 at 7:52 PM
$IRD Hit the area in the downside. Now we bulid a floor for the next upmove Key is the orange Line a Break above 4.68 and we will See the next Leg Up. Targets marked Green in the Chart.
0 · Reply
Um8a123
Um8a123 Jun. 30 at 12:38 AM
$IRD it’s gonna blow any of these day!
0 · Reply
signaljumper
signaljumper Jun. 29 at 4:59 PM
$IRD WE only need some Volume then we will move north
0 · Reply